MedTrace Logo

sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis

NCT02924701 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 168

Last updated 2022-08-12

No results posted yet for this study

Summary

Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR correlate with disease severity in patients with PBC, and whether sCD163 and sMR can predict short term disease progression, changes in quality of life and death in these patients.

Conditions

  • Primary Biliary Cirrhosis
  • Liver Inflammation

Interventions

OTHER

Blood samples, fibroscan and questionaires

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2031-01-31
Completion
2031-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02924701 on ClinicalTrials.gov